Impact of Novel Medications and Out-Of-Pocket Costs in Managing Cardiovascular Disease

Panelists discuss financial obstacles, out-of-pocket costs, prior authorizations, and the inpatient/outpatient care paradigm.

EP: 1.Disparities in Cardiovascular Care for Diverse Populations

EP: 2.Innovation vs Access: Supporting Underserved Communities

EP: 3.Exploring Polypharmacy: Adherence, Communication, and Outcomes

EP: 4.Gender-Based Disparities in Cardiovascular Disease

EP: 5.Peripheral Arterial Disease Awareness for Minority Populations

EP: 6.Community Partnership: Increasing Public Awareness of CVD

EP: 7.Recent Data Reveals Disparities in Cardiovascular Care

EP: 8.Identifying Social Determinants of Health in Cardiovascular Care

Now Viewing

EP: 9.Impact of Novel Medications and Out-Of-Pocket Costs in Managing Cardiovascular Disease

EP: 10.Developing Practical Solutions to Improve Cardiovascular Care

EP: 11.Advancing Cardiovascular Care Through Technological Innovation

EP: 12.Desired Technology Innovations to Prevent Cardiovascular Disease

EP: 13.Measuring Implicit Bias

EP: 14.Achieving Equitable Representation in Clinical Studies

EP: 15.Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion

Related Videos

Related Content

Advertisement

May 28th 2025

Punctal Plugs Effective, Safe in Treating Moderate, Severe Dry Eye Disease

Julia Bonavitacola

Tear film stability, tear production, ocular surface health, and symptoms were all significantly improved with the use of punctal plugs.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 23rd 2025

5 Rare Disorders Named for Pioneering Female Scientists

Maggie L. Shaw

Explore 5 rare genetic and neurological disorders named after pioneering women in medicine, highlighting their significant contributions to previously unknown conditions.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 22nd 2025

FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype

Brooke McCormick

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

May 21st 2025

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

Laura Joszt, MA Eileen Peng, PharmD

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.

Related Content

Advertisement

May 28th 2025

Punctal Plugs Effective, Safe in Treating Moderate, Severe Dry Eye Disease

Julia Bonavitacola

Tear film stability, tear production, ocular surface health, and symptoms were all significantly improved with the use of punctal plugs.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 23rd 2025

5 Rare Disorders Named for Pioneering Female Scientists

Maggie L. Shaw

Explore 5 rare genetic and neurological disorders named after pioneering women in medicine, highlighting their significant contributions to previously unknown conditions.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 22nd 2025

FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype

Brooke McCormick

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

May 21st 2025

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

Laura Joszt, MA Eileen Peng, PharmD

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.